Differences in risk factors for breast cancer molecular subtypes in a population-based study
- PMID: 17372238
- DOI: 10.1158/1055-9965.EPI-06-0806
Differences in risk factors for breast cancer molecular subtypes in a population-based study
Abstract
Analysis of gene expression data suggests that breast cancers are divisible into molecular subtypes which have distinct clinical features. This study evaluates whether pathologic features and etiologic associations differ among molecular subtypes. We evaluated 804 women with invasive breast cancers and 2,502 controls participating in a Polish Breast Cancer Study. Immunohistochemical stains for estrogen receptor alpha, progesterone receptor, human epidermal growth factor receptors (HER2 and HER1), and cytokeratin 5 were used to classify cases into five molecular subtypes: luminal A, luminal B, HER2-expresing, basal-like, and unclassified. Relative risks were estimated using adjusted odds ratios and 95% confidence intervals. We observed that compared with the predominant luminal A tumors (69%), other subtypes were associated with unfavorable clinical features at diagnosis, especially HER2-expressing (8%) and basal-like (12%) tumors. Increasing body mass index significantly reduced the risk of luminal A tumors among premenopausal women (odds ratios, 0.71; 95% confidence intervals, 0.57-0.88 per five-unit increase), whereas it did not reduce risk for basal-like tumors (1.18; 0.86-1.64; P(heterogeneity) = 0.003). On the other hand, reduced risk associated with increasing age at menarche was stronger for basal-like (0.78; 0.68-0.89 per 2-year increase) than luminal A tumors (0.90; 0.95-1.08; P(heterogeneity) = 0.0009). Although family history increased risk for all subtypes (except for unclassified tumors), the magnitude of the relative risk was highest for basal-like tumors. Results from this study have shown that breast cancer risk factors may vary by molecular subtypes identified in expression studies, suggesting etiologic, in addition to clinical, heterogeneity of breast cancer.
Similar articles
-
Immunohistochemistry-based subtyping of breast carcinoma in Egyptian women: a clinicopathologic study on 125 patients.Ann Diagn Pathol. 2014 Feb;18(1):21-6. doi: 10.1016/j.anndiagpath.2013.10.005. Epub 2013 Oct 30. Ann Diagn Pathol. 2014. PMID: 24321463
-
Characterization of breast cancer subtypes by quantitative assessment of biological parameters: relationship with clinicopathological characteristics, biological features and prognosis.Eur J Obstet Gynecol Reprod Biol. 2008 Dec;141(2):147-52. doi: 10.1016/j.ejogrb.2008.07.021. Epub 2008 Sep 2. Eur J Obstet Gynecol Reprod Biol. 2008. PMID: 18768247
-
Reproductive risk factors in relation to molecular subtypes of breast cancer: Results from the nurses' health studies.Int J Cancer. 2016 May 15;138(10):2346-56. doi: 10.1002/ijc.29968. Epub 2016 Feb 8. Int J Cancer. 2016. PMID: 26684063 Free PMC article.
-
A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments.Breast Cancer Res Treat. 2011 Nov;130(2):489-98. doi: 10.1007/s10549-011-1709-6. Epub 2011 Aug 12. Breast Cancer Res Treat. 2011. PMID: 21837481
-
Established breast cancer risk factors and risk of intrinsic tumor subtypes.Biochim Biophys Acta. 2015 Aug;1856(1):73-85. doi: 10.1016/j.bbcan.2015.06.002. Epub 2015 Jun 10. Biochim Biophys Acta. 2015. PMID: 26071880 Review.
Cited by
-
The Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial Pathology Tissue Resource.Cancer Epidemiol Biomarkers Prev. 2016 Dec;25(12):1635-1642. doi: 10.1158/1055-9965.EPI-16-0506. Epub 2016 Sep 15. Cancer Epidemiol Biomarkers Prev. 2016. PMID: 27635065 Free PMC article. Clinical Trial.
-
Protooncogenic Role of ARHGAP11A and ARHGAP11B in Invasive Ductal Carcinoma: Two Promising Breast Cancer Biomarkers.Biomed Res Int. 2023 Nov 23;2023:8236853. doi: 10.1155/2023/8236853. eCollection 2023. Biomed Res Int. 2023. PMID: 38046902 Free PMC article.
-
Demographic and clinico-pathological characteristics in patients with triple-negative and non-triple-negative breast cancer.Med Oncol. 2011 Dec;28 Suppl 1:S75-9. doi: 10.1007/s12032-010-9715-9. Epub 2010 Oct 21. Med Oncol. 2011. PMID: 20963641
-
Non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk: differences by molecular subtype.Cancer Causes Control. 2011 Jul;22(7):965-75. doi: 10.1007/s10552-011-9769-9. Epub 2011 Apr 23. Cancer Causes Control. 2011. PMID: 21516318 Free PMC article.
-
Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study.BMC Cancer. 2010 Nov 30;10:653. doi: 10.1186/1471-2407-10-653. BMC Cancer. 2010. PMID: 21118480 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous